GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » Asset Turnover

China Pharma Holding (China Pharma Holding) Asset Turnover : 0.08 (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. China Pharma Holding's Revenue for the three months ended in Mar. 2024 was $1.37 Mil. China Pharma Holding's Total Assets for the quarter that ended in Mar. 2024 was $16.33 Mil. Therefore, China Pharma Holding's Asset Turnover for the quarter that ended in Mar. 2024 was 0.08.

Asset Turnover is linked to ROE % through Du Pont Formula. China Pharma Holding's annualized ROE % for the quarter that ended in Mar. 2024 was -48.57%. It is also linked to ROA % through Du Pont Formula. China Pharma Holding's annualized ROA % for the quarter that ended in Mar. 2024 was -23.42%.


China Pharma Holding Asset Turnover Historical Data

The historical data trend for China Pharma Holding's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding Asset Turnover Chart

China Pharma Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.50 0.44 0.40 0.41

China Pharma Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.07 0.12 0.14 0.08

Competitive Comparison of China Pharma Holding's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Pharma Holding's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Asset Turnover distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Asset Turnover falls into.



China Pharma Holding Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

China Pharma Holding's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=7.011/( (17.784+16.469)/ 2 )
=7.011/17.1265
=0.41

China Pharma Holding's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=1.37/( (16.469+16.19)/ 2 )
=1.37/16.3295
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


China Pharma Holding  (OTCPK:CPHI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

China Pharma Holding's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-3.824/7.8735
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.824 / 5.48)*(5.48 / 16.3295)*(16.3295/ 7.8735)
=Net Margin %*Asset Turnover*Equity Multiplier
=-69.78 %*0.3356*2.074
=ROA %*Equity Multiplier
=-23.42 %*2.074
=-48.57 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

China Pharma Holding's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-3.824/16.3295
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.824 / 5.48)*(5.48 / 16.3295)
=Net Margin %*Asset Turnover
=-69.78 %*0.3356
=-23.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


China Pharma Holding Asset Turnover Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


China Pharma Holding (China Pharma Holding) Business Description

Traded in Other Exchanges
N/A
Address
Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Executives
Ke Deng 10 percent owner NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung officer: Chief Financial Officer 72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett director 4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang director NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong director NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui director, 10 percent owner FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li officer: President and CEO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang officer: Secretary NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu officer: CFO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond 10 percent owner 174 FM 1830, ARGYLE TX 76226
David F Brigante 10 percent owner 174FM 1830, ARGYLE TX 76226
Marat Rosenberg 10 percent owner 17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp 10 percent owner 174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc 10 percent owner 174 FM 1830, ARGYLE TX 76226
Timothy P Halter director, 10 percent owner, officer: CEO, President & CFO 174 FM 1830, ARGYLE TX 76226